References
- Buxbaum JD, Chernew ME, Fendrick AM, Cutler DM. Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990–2015: study examines the conditions most responsible for changing us life expectancy and how public health, pharmaceuticals, other medical care, and other factors may have contributed to the changes. Health Aff. 39(9), 1546–1556 (2020).
- US Food and Drug Administration (FDA). New drugs at FDA: CDER's new molecular entities and new therapeutic biological products. www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products (13 January 2023).
- Howlader N, Forjaz G, Mooradian MJ et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383(7), 640–649 (2020).
- Li M, Goldman DP, Chen AJ. Spending on targeted therapies reduced mortality in patients with advanced-stage breast cancer: study examines spending on targeted therapies for patients with advanced-stage breast cancer and the impact on mortality. Health Aff. 40(5), 763–771 (2021).
- Macewan JP, Dennen S, Kee R, Ali F, Shafrin J, Batt K. Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016. J. Med. Econ. 23(12), 1558–1569 (2020).
- Li M, Garrison L Jr, Lee W, Kowal S, Wong W, Veenstra D. A pragmatic guide to assessing real option value for medical technologies. Value Health doi:10.1016/j.jval.2022.05.014 (2022).
- Lee W, Li M, Wong WB, To TM, Garrison LP, Veenstra DL. Modeling the ex post real option value in metastatic melanoma using real-world data. Value in Health 24(12), 1746–1753 (2021).
- Li M, Elsisi Z, Wong WB, Kowal S, Veenstra DL, Garrison LP. Do future innovations in development influence oncologists' treatment recommendations today? A survey of U.S. oncologists. J. Clin. Oncol. 41(Suppl. 16), e24004–e24004 (2023).
- Lee W, Wong WB, Kowal S, Garrison LP Jr, Veenstra DL, Li M. Modeling the Ex Ante clinical real option value in an innovative therapeutic area: ALK-positive non-small-cell lung cancer. Pharmaco Economics 40(6), 623–631 (2022).
- Li M, Basu A, Bennette C, Veenstra D, Garrison LP Jr. How does option value affect the potential cost-effectiveness of a treatment? The case of ipilimumab for metastatic melanoma. Value Health 22(7), 777–784 (2019).
- Sanchez Y, Penrod JR, Qiu XL, Romley J, Thornton Snider J, Philipson T. The option value of innovative treatments in the context of chronic myeloid leukemia. Am. J. Manag. Care 18(Suppl. 11), S265–S271 (2012).
- Snider JT, Batt K, Wu Y, Tebeka MG, Seabury S. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma. Am. J. Manag. Care 23, e340–e346 (2017).
- Wong WB, To TM, Li M, Lee W, Veenstra DL, Garrison LP Jr. Real-world evidence for option value in metastatic melanoma. J. Manag. Care Spec. Pharm. 27(11), 1546–1555 (2021).
- FDA. Accelerated approval program. www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program (13 January 2023).
- Beakes-Read G, Neisser M, Frey P, Guarducci M. Analysis of FDA's accelerated approval program performance December 1992-December 2021. Ther. Innov. Regul. Sci. 56(5), 698–703 (2022).
- Beaver JA, Howie LJ, Pelosof L et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 4(6), 849–856 (2018).
- Beaver JA, Pazdur R. “Dangling” accelerated approvals in oncology. N. Engl. J. Med. 384(18), e68 (2021).
- Kaltenboeck A, Mehlman A, Pearson SD. Potential policy reforms to strengthen the accelerated approval pathway. J. Comp. Eff. Res. 10(16), 1177–1186 (2021).
- Vokinger KN, Kesselheim AS, Glaus CEG, Hwang TJ. Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021. JAMA Health Forum. 3(8), e222685–e222685 (2022).
- Ladd V. The FDA's accelerated approval process is working (2021). https://morningconsult.com/opinions/fdas-accelerated-approval-process-working/ ( 13 January 2023).
- Gloy V, Schmitt AM, Düblin P et al. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. Int. J. Cancer 152(12), 2474–2484 (2023).
- Chambers JD, Thorat T, Wilkinson CL, Neumann PJ. Drugs cleared through the FDA's expedited review offer greater gains than drugs approved by conventional process. Health Aff. 36(8), 1408–1415 (2017).
- Birnbaum B, Nussbaum N, Seidl-Rathkopf K et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv preprint arXiv:2001.09765 (2020).
- Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv doi:10.1101/2020.03.16.20037143 (2020).
- CancerMPact® Patient metrics, Cerner Enviza. www.cancermpact.com (24 January 2023).
- Institute for Clinical and Economic Review. Strengthening the accelerated approval pathway: an analysis of potential policy reforms and their impact on uncertainty, access, innovation, and costs (2021). https://icer.org/wp-content/uploads/2021/04/Strengthening-the-Accelerated-Approval-Pathway-_-ICER-White-Paper-_-April-2021.pdf ( 22 February 2023).
- FOCR data on file presentation.
- Benjamin DJ, Lythgoe MP. The FDA's latest draft guidance on accelerated approvals – one step forward, two steps back? Nat. Rev. Clin. Oncol. 20(9), 577–578 (2023).
- Gyawali B, Kesselheim AS, Ross JS. The accelerated approval program for cancer drugs – finding the right balance. N. Engl. J. Med. 389(11), 968–971 (2023).
- Wong W, Kowal S, To TM et al. HPR6 beyond conventional clinical value: estimating the impact of accelerated approvals on therapeutic bridging between innovative therapies. Value in Health 26, S211–S212 (2023). www.ispor.org/docs/default-source/intl2023/gnea046-z-wong-42-x-72-l-postersolid-tumors-rweispor24apr23-pdf.pdf?sfvrsn=9b10f1b0_0